Skip to main content

Advertisement

SpringerLink
Log in

Galangin inhibits hypertrophic scar formation via ALK5/Smad2/3 signaling pathway

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

A Correction to this article was published on 06 March 2020

This article has been updated

Abstract

Hypertrophic scar (HS) is characterized by excessive fibrosis associated with aberrant function of fibroblasts. Currently, no satisfactory drug has been developed to treat the disease. Here we found that a flavonoid natural product, galangin, could significantly attenuate hypertrophic scar formation in a mechanical load-induced mouse model. Both in vivo and in vitro studies demonstrated that galangin remarkably inhibited collagen production, proliferation, and activation of fibroblasts. Besides, galangin suppressed the contractile ability of hypertrophic scar fibroblasts. Further Western blot analysis revealed that galangin dose-dependently down-regulated Smad2 and Smad3 phosphorylation. Such bioactivity of galangin resulted from its selective targeting to the activin receptor-like kinase 5 (ALK5) was demonstrated by ALK5 knockdown and over-expression experiments. Taken together, this compound could simultaneously inhibit both the accumulation of collagen and abnormal activation/proliferation of fibroblasts, which were the two pivotal factors for hypertrophic scar formation, thus suggesting that galangin serves as a potential agent for treatment of HS or other fibroproliferative disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Change history

  • 06 March 2020

    In the original article, Figs.��3b, 4a, c and 5d were published incorrectly. The correct version of the figures are provided in this correction.

  • 06 March 2020

    In the original article, Figs.��3b, 4a, c and 5d were published incorrectly. The correct version of the figures are provided in this correction.

References

  1. van den Broek LJ, Limandjaja GC, Niessen FB, Gibbs S (2014) Human hypertrophic and keloid scar models: principles, limitations and future challenges from a tissue engineering perspective. Exp Dermatol 23:382–386. doi:10.1111/exd.12419

    Article  PubMed Central  PubMed  Google Scholar 

  2. Zielins ER, Atashroo DA, Maan ZN, Duscher D, Walmsley GG, Hu M, Senarath-Yapa K, McArdle A, Tevlin R, Wearda T, Paik KJ, Duldulao C, Hong WX, Gurtner GC, Longaker MT (2014) Wound healing: an update. Regen Med 9:817–830. doi:10.2217/rme.14.54

    Article  CAS  PubMed  Google Scholar 

  3. Rabello FB, Souza CD, Farina Junior JA (2014) Update on hypertrophic scar treatment. Clinics (Sao Paulo) 69:565–573

    Article  Google Scholar 

  4. Vrijman C, van Drooge AM, Limpens J, Bos JD, van der Veen JP, Spuls PI, Wolkerstorfer A (2011) Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. Br J Dermatol 165:934–942. doi:10.1111/j.1365-2133.2011.10492.x

    Article  CAS  PubMed  Google Scholar 

  5. Profyris C, Tziotzios C, Do Vale I (2012) Cutaneous scarring: pathophysiology, molecular mechanisms, and scar reduction therapeutics: part I. The molecular basis of scar formation. J Am Acad Dermatol 66:1–10. doi:10.1016/j.jaad.2011.05.055

    Article  CAS  PubMed  Google Scholar 

  6. Zhu Z, Ding J, Shankowsky HA, Tredget EE (2013) The molecular mechanism of hypertrophic scar. J Cell Commun Signal 7:239–252. doi:10.1007/s12079-013-0195-5

    Article  PubMed Central  PubMed  Google Scholar 

  7. Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature 453:314–321. doi:10.1038/nature07039

    Article  CAS  PubMed  Google Scholar 

  8. Darby IA, Laverdet B, Bonte F, Desmouliere A (2014) Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Investig Dermatol 7:301–311. doi:10.2147/ccid.s50046

    PubMed Central  PubMed  Google Scholar 

  9. Wong VW, Rustad KC, Akaishi S, Sorkin M, Glotzbach JP, Januszyk M, Nelson ER, Levi K, Paterno J, Vial IN, Kuang AA, Longaker MT, Gurtner GC (2012) Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat Med 18:148–152. doi:10.1038/nm.2574

    Article  PubMed Central  CAS  Google Scholar 

  10. Santos EO, Kabeya LM, Figueiredo-Rinhel AS, Marchi LF, Andrade MF, Piatesi F, Paoliello-Paschoalato AB, Azzolini AE, Lucisano-Valim YM (2014) Flavonols modulate the effector functions of healthy individuals’ immune complex-stimulated neutrophils: a therapeutic perspective for rheumatoid arthritis. Int Immunopharmacol 21:102–111. doi:10.1016/j.intimp.2014.04.014

    Article  CAS  PubMed  Google Scholar 

  11. Kumar S, Alagawadi KR (2013) Anti-obesity effects of galangin, a pancreatic lipase inhibitor in cafeteria diet fed female rats. Pharm Biol 51:607–613. doi:10.3109/13880209.2012.757327

    Article  CAS  PubMed  Google Scholar 

  12. Chien ST, Shi MD, Lee YC, Te CC, Shih YW (2015) Galangin, a novel dietary flavonoid, attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells. Cancer Cell Int 15:15. doi:10.1186/s12935-015-0168-2

    Article  PubMed Central  PubMed  Google Scholar 

  13. Li S, Wu C, Zhu L, Gao J, Fang J, Li D, Fu M, Liang R, Wang L, Cheng M, Yang H (2012) By improving regional cortical blood flow, attenuating mitochondrial dysfunction and sequential apoptosis galangin acts as a potential neuroprotective agent after acute ischemic stroke. Molecules 17:13403–13423. doi:10.3390/molecules171113403

    Article  CAS  PubMed  Google Scholar 

  14. Madduma Hewage SR, Piao MJ, Kim KC, Cha JW, Han X, Choi YH, Chae S, Hyun JW (2015) Galangin (3,5,7-trihydroxyflavone) shields human keratinocytes from ultraviolet B-induced oxidative stress. Biomol Ther (Seoul) 23:165–173. doi:10.4062/biomolther.2014.130

    Article  Google Scholar 

  15. Choi JK, Kim SH (2014) Inhibitory effect of galangin on atopic dermatitis-like skin lesions. Food Chem Toxicol 68:135–141. doi:10.1016/j.fct.2014.03.021

    Article  CAS  PubMed  Google Scholar 

  16. Wang X, Gong G, Yang W, Li Y, Jiang M, Li L (2013) Antifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis model. Environ Toxicol Pharmacol 36:288–295. doi:10.1016/j.etap.2013.04.004

    Article  CAS  PubMed  Google Scholar 

  17. Kosla J, Dvorak M, Cermak V (2013) Molecular analysis of the TGF-beta controlled gene expression program in chicken embryo dermal myofibroblasts. Gene 513:90–100. doi:10.1016/j.gene.2012.10.069

    Article  CAS  PubMed  Google Scholar 

  18. Woeller CF, O’Loughlin CW, Roztocil E, Feldon SE, Phipps RP (2015) Salinomycin and other polyether ionophores are a new class of antiscarring agent. J Biol Chem 290:3563–3575. doi:10.1074/jbc.M114.601872

    Article  CAS  PubMed  Google Scholar 

  19. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 16:5353–5362. doi:10.1093/emboj/16.17.5353

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Aarabi S, Bhatt KA, Shi Y, Paterno J, Chang EI, Loh SA, Holmes JW, Longaker MT, Yee H, Gurtner GC (2007) Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. FASEB J 21:3250–3261. doi:10.1096/fj.07-8218com

    Article  CAS  PubMed  Google Scholar 

  21. Hinz B (2007) Formation and function of the myofibroblast during tissue repair. J Investig Dermatol 127:526–537. doi:10.1038/sj.jid.5700613

    Article  CAS  PubMed  Google Scholar 

  22. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028–1040. doi:10.1038/nm.2807

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA Jr, Wrana JL, Falb D (1997) The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89:1165–1173

    Article  CAS  PubMed  Google Scholar 

  24. Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465–471. doi:10.1038/37284

    Article  CAS  PubMed  Google Scholar 

  25. Liu XJ, Xu MJ, Fan ST, Wu Z, Li J, Yang XM, Wang YH, Xu J, Zhang ZG (2013) Xiamenmycin attenuates hypertrophic scars by suppressing local inflammation and the effects of mechanical stress. J Investig Dermatol 133:1351–1360. doi:10.1038/jid.2012.486

    Article  CAS  PubMed  Google Scholar 

  26. Ledon JA, Savas J, Franca K, Chacon A, Nouri K (2013) Intralesional treatment for keloids and hypertrophic scars: a review. Dermatol Surg 39:1745–1757. doi:10.1111/dsu.12346

    Article  CAS  PubMed  Google Scholar 

  27. Leventhal D, Furr M, Reiter D (2006) Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg 8:362–368. doi:10.1001/archfaci.8.6.362

    Article  PubMed  Google Scholar 

  28. English RS, Shenefelt PD (1999) Keloids and hypertrophic scars. Dermatol Surg 25:631–638

    Article  CAS  PubMed  Google Scholar 

  29. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG (2011) Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 17:113–125. doi:10.2119/molmed.2009.00153

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Desmouliere A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7–12. doi:10.1111/j.1067-1927.2005.130102.x

    Article  PubMed  Google Scholar 

  31. Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, Janson C, Smith W, Krysa G, Boullay V, De Gouville AC, Huet S, Hartley D (2004) Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem 47:4494–4506. doi:10.1021/jm0400247

    Article  CAS  PubMed  Google Scholar 

  32. Sapitro J, Dunmire JJ, Scott SE, Sutariya V, Geldenhuys WJ, Hewit M, Yue BY, Nakamura H (2010) Suppression of transforming growth factor-beta effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor. Mol Vis 16:1880–1892

    PubMed Central  CAS  PubMed  Google Scholar 

  33. Shen N, Lin H, Wu T, Wang D, Wang W, Xie H, Zhang J, Feng Z (2013) Inhibition of TGF-beta1-receptor posttranslational core fucosylation attenuates rat renal interstitial fibrosis. Kidney Int 84:64–77. doi:10.1038/ki.2013.82

    Article  CAS  PubMed  Google Scholar 

  34. Higashiyama H, Yoshimoto D, Kaise T, Matsubara S, Fujiwara M, Kikkawa H, Asano S, Kinoshita M (2007) Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp Mol Pathol 83:39–46. doi:10.1016/j.yexmp.2006.12.003

    Article  CAS  PubMed  Google Scholar 

  35. Park JH, Ryu SH, Choi EK, Ahn SD, Park E, Choi KC, Lee SW (2015) SKI2162, an inhibitor of the TGF-beta type I receptor (ALK5), inhibits radiation-induced fibrosis in mice. Oncotarget 6:4171–4179

    Article  PubMed Central  PubMed  Google Scholar 

  36. Shang Y, Yu D, Hao L (2015) Liposome–adenoviral hTERT-siRNA knockdown in fibroblasts from keloids reduce telomere length and fibroblast growth. Cell Biochem Biophys. doi:10.1007/s12013-014-0476-5

    Google Scholar 

  37. Wang YW, Liou NH, Cherng JH, Chang SJ, Ma KH, Fu E, Liu JC, Dai NT (2014) siRNA-targeting transforming growth factor-beta type I receptor reduces wound scarring and extracellular matrix deposition of scar tissue. J Investig Dermatol 134:2016–2025. doi:10.1038/jid.2014.84

    Article  CAS  PubMed  Google Scholar 

  38. Aoki M, Miyake K, Ogawa R, Dohi T, Akaishi S, Hyakusoku H, Shimada T (2014) siRNA knockdown of tissue inhibitor of metalloproteinase-1 in keloid fibroblasts leads to degradation of collagen type I. J Investig Dermatol 134:818–826. doi:10.1038/jid.2013.396

    Article  CAS  PubMed  Google Scholar 

  39. Dehshahri A, Sadeghpour H (2015) Surface decorations of poly(amidoamine) dendrimer by various pendant moieties for improved delivery of nucleic acid materials. Colloids Surf B Biointerfaces 132:85–102. doi:10.1016/j.colsurfb.2015.05.006

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from the key project of the National Natural Science Foundation (No. 81230042) and the National Key Project of Scientific and Technical Supporting Programs Funded by Ministry of Science & Technology of China (No. 2012BAI11B03).

Author information

Author notes

    Authors and Affiliations

    1. Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, 639 Zhizaoju Road, Shanghai, 200011, China

      Yifan Zhang, Shengzhou Shan, Jing Wang, Jia Zhou & Qingfeng Li

    2. Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

      Xinyu Cheng

    3. Clinical College of General Hospital of Beijing Military Region, Anhui Medical University, Hefei, China

      Bo Yi

    Authors
    1. Yifan Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Shengzhou Shan
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Jing Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Xinyu Cheng
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Bo Yi
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Jia Zhou
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Qingfeng Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Jia Zhou or Qingfeng Li.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Ethics approval

    Ethical approval was given by the Animal Care and Use Committee of Shanghai Jiao Tong University.

    Additional information

    Yifan Zhang and Shengzhou Shan have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Zhang, Y., Shan, S., Wang, J. et al. Galangin inhibits hypertrophic scar formation via ALK5/Smad2/3 signaling pathway. Mol Cell Biochem 413, 109–118 (2016). https://doi.org/10.1007/s11010-015-2644-3

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11010-015-2644-3

    Keywords

    Search

    Navigation